Immunophenotyping in systemic mastocytosis diagnosis: CD25 positive alone is more informative than the CD25 and/or CD2 WHO criterion

Modern Pathology

Volumn 25, Issue 4, 2012, Pages 516-521

  Morgado, José Mário T ^a,b   Sánchez Mũoz, Laura ^a,b   Teodósio, Cristina G ^b,c   Jara Acevedo, Maria ^b,c   Álvarez Twose, Iván ^a,b   Matito, Almudena ^a,b   Fernández Nũez, Elisa ^b,c   García Montero, Andrés ^b,c   Orfao, Alberto ^b,c   Escribano, Luís ^a,b  

^a HOSPITAL VIRGEN DE LA SALUD   (Spain)

^b Instituto de Estudios de Mastocitosis de Castilla La Mancha   (Spain)

^c UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

CD2; CD25; diagnostic criteria; immunophenotype; systemic mastocytosis

Indexed keywords

CD2 ANTIGEN;

ARTICLE; BONE MARROW CELL; CD25+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MAST CELL; MASTOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; WORLD HEALTH ORGANIZATION;

ANTIGENS, CD2; BIOLOGICAL MARKERS; BONE MARROW EXAMINATION; CHI-SQUARE DISTRIBUTION; FLOW CYTOMETRY; GUIDELINE ADHERENCE; HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MAST CELLS; MASTOCYTOSIS, SYSTEMIC; OBSERVER VARIATION; PHENOTYPE; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SPAIN; WORLD HEALTH ORGANIZATION;

EID: 84859435404     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.192     Document Type: Article

References (22)

1. Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001;25:603-625. (Pubitemid 32506768)
2. Valent P, Horny HP, Li CY, et al. Mastocytosis (mast cell disease). World Health Organization (WHO) Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2001;291-302.
3. Horny HP, Metcalfe DD, Bennet JM, et al. Mastocytosis. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. IARC: Lyon, France, 2008. pp 54-63.
4. Horny HP, Sillaber C, Menke D, et al. Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am J Surg Pathol 1998;22:1132-1140. (Pubitemid 28411072)
5. Sotlar K, Horny HP, Simonitsch I, et al. CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol 2004;28:1319-1325. (Pubitemid 39336370)
6. Krokowski M, Sotlar K, Krauth MT, et al. Delineation of patterns of bone marrow mast cell infiltration in systemic mastocytosis: value of CD25, correlation with subvariants of the disease, and separation from mast cell hyperplasia. Am J Clin Pathol 2005;124:560-568. (Pubitemid 41395637)
7. Orfao A, Escribano L, Villarrubia J, et al. Flow cytometric analysis of mast cells from normal and pathological human bone marrow samples. Identification and enumeration. Am J Pathol 1996;149:1493-1499. (Pubitemid 26363956)
8. Escribano L, Orfao A, Diaz-Agustin B, et al. Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood 1998;91:2731-2736. (Pubitemid 28227522)
9. Escribano L, Diaz-Agustin B, López A, et al. Immunophenotypic analysis of mast cells in mastocytosis: when and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA). Cytometry B Clin Cytom 2004;58B:1-8. (Pubitemid 38332714)
10. Teodosio C, Garcia-Montero AC, Jara-Acevedo M, et al. Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. J Allergy Clin Immunol 2010;125: 719-726.
11. Sotlar K, Fridrich C, Mall A, et al. Detection of c-kit point mutation Asp-816-4 Val in microdissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemia. Leuk Res 2002;26:979-984. (Pubitemid 35287206)
12. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al. KIT mutation in mast cells and other bone marrow haematopoietic cell lineages in systemic mast cell disorders. A prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006;108:2366-2372. (Pubitemid 44497521)
13. Escribano L, Orfao A, Villarrubia J, et al. Immunophenotypic characterization of human bone marrow mast cells. A flow cytometric study of normal and pathological bone marrow samples. An Cell Pathol 1998;16:151-159. (Pubitemid 28293814)
14. Pardanani A, Kimlinger T, Reeder T, et al. Bone marrow mast cell immunophenotyping in adults with mast cell disease: a prospective study of 33 patients. Leuk Res 2004;28:777-783. (Pubitemid 38760039)
15. Bodni RA, Sapia S, Galeano A, et al. Indolent systemic mast cell disease: immunophenotypic characterization of bone marrow mast cells by flow cytometry. J Eur Acad Dermatol Venereol 2003;17:160-166. (Pubitemid 36416781)
16. Pardanani A, Kimlinger TK, Reeder TL, et al. Differential expression of CD2 on neoplastic mast cells in patients with systemic mast cell disease with and without an associated clonal haematological disorder. Br J Haematol 2003;120:691-694. (Pubitemid 36255872)
17. Escribano L, Orfao A, Villarrubia J, et al. Expression of lymphoid-associated antigens in mast cells: report of a case of systemic mast cell disease. Br J Haematol 1995;91:941-943.
18. Escribano L, Alvarez-Twose I, Sanchez-Munoz L, et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol 2009;124:514-521.
19. Alvarez-Twose I, Gonzalez de Olano D, Sanchez-Munoz L, et al. Clinical, biological and molecular characteristics of systemic mast cell disorders presenting with severe mediator-related symptoms. J Allergy Clin Immunol 2010;125:1269-1278.
20. Baumgartner C, Sonneck K, Krauth MT, et al. Immunohistochemical assessment of CD25 is equally sensitive and diagnostic in mastocytosis compared to flow cytometry. Eur J Clin Invest 2008;38:326-335. (Pubitemid 351489909)
21. Sanchez-Munoz L, Alvarez-Twose I, Garcia-Montero AC, et al. Evaluation of the WHO criteria for the classification of patients with mastocytosis. Mod Pathol 2011.
22. Caruso A, Licenziati S, Corulli M, et al. Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation. Cytometry 1997;27:71-76. (Pubitemid 27059784)